Evaxion A/S (EVAX)

NASDAQ: EVAX · Real-Time Price · USD
2.610
-0.070 (-2.61%)
At close: Aug 1, 2025, 4:00 PM
2.570
-0.040 (-1.53%)
After-hours: Aug 1, 2025, 5:18 PM EDT
-2.61%
Market Cap16.49M
Revenue (ttm)3.29M
Net Income (ttm)-13.34M
Shares Out 6.32M
EPS (ttm)-6.01
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume70,477
Open2.680
Previous Close2.680
Day's Range2.450 - 2.722
52-Week Range1.200 - 17.750
Beta0.12
AnalystsStrong Buy
Price Target10.00 (+283.14%)
Earnings DateAug 13, 2025

About AGR

Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based cancer vaccine that has completed Phase 1/2a trial to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers, including non-small cell lung cancer. Its programs also include vacci... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Feb 5, 2021
Employees 46
Stock Exchange NASDAQ
Ticker Symbol EVAX
Full Company Profile

Financial Performance

In 2024, Evaxion's revenue was $3.34 million, an increase of 4480.82% compared to the previous year's $73,000. Losses were -$10.57 million, -52.24% less than in 2023.

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for EVAX stock is "Strong Buy." The 12-month stock price target is $10.0, which is an increase of 283.14% from the latest price.

Price Target
$10.0
(283.14% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

COPENHAGEN, Denmark, July 25, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will be presenting two-year cl...

7 days ago - GlobeNewsWire

Evaxion finalizes agreement with EIB to convert debt into equity

COPENHAGEN, Denmark, July 11, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has finalized its agreement wi...

21 days ago - GlobeNewsWire

Evaxion announces changes to Executive Management to optimize the value of proprietary AI-Immunology™ platform and portfolio

COPENHAGEN, Denmark, July 1, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces several key executive...

4 weeks ago - GlobeNewsWire

Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus

COPENHAGEN, Denmark, June 25, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, initiates work to develop a ne...

5 weeks ago - GlobeNewsWire

Evaxion receives grant funding to design new polio vaccine

COPENHAGEN, Denmark, June 3, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, receives funding support from t...

2 months ago - GlobeNewsWire

Evaxion Biotech A/S (EVAX) Q1 2025 Earnings Conference Call Transcript

Evaxion Biotech A/S (EVAX) Q1 2025 Earnings Conference Call May 27, 2025 8:30 PM ET Company Participants Christian Kanstrup - CEO Birgitte Rono - Chief Scientific Officer Thomas Schmidt - CFO Conferen...

2 months ago - Seeking Alpha

Evaxion announces business update and first quarter 2025 financial results

COPENHAGEN, Denmark, May 27, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and an...

2 months ago - GlobeNewsWire

Evaxion: Progress Unrecognized By Market And A Catalyst-Full 2025

Evaxion has demonstrated impressive in-house capabilities for discovering and developing vaccine candidates for both infectious diseases and oncology indications. Partnership with MSD, albeit heavily ...

2 months ago - Seeking Alpha

Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025

COPENHAGEN, Denmark, May 23, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update ...

2 months ago - GlobeNewsWire

Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01

COPENHAGEN, Denmark, May 22, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has dosed the first patient in ...

2 months ago - GlobeNewsWire

80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - Evaxion presents striking EVX-01 data at the AACR Annual meeting

COPENHAGEN, Denmark, April 28, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces new data un...

3 months ago - GlobeNewsWire

Evaxion to present at World Vaccine Congress

COPENHAGEN, Denmark, April 10, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will give two present...

4 months ago - GlobeNewsWire

Evaxion Biotech A/S (EVAX) Q4 2024 Earnings Call Transcript

Evaxion Biotech A/S (EVAX) Q4 2024 Earnings Conference Call April 1, 2025 8:30 AM ET Company Participants Christian Kanstrup - Chief Executive Officer Birgitte Rønø - Chief Scientific Officer Thomas S...

4 months ago - Seeking Alpha

Evaxion to announce business update and full year 2024 financial results on April 1, 2025

COPENHAGEN, Denmark, March 27, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a busine...

4 months ago - GlobeNewsWire

Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting

COPENHAGEN, Denmark, March 25, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will present new data...

4 months ago - GlobeNewsWire

Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package

COPENHAGEN, Denmark, February 25, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will further enhan...

5 months ago - GlobeNewsWire

Evaxion announces closing of $10.8 million public offering

COPENHAGEN, Denmark, January 31, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced the...

6 months ago - GlobeNewsWire

Evaxion announces pricing of $10.8 million public offering

COPENHAGEN, Denmark, January 30, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced the...

6 months ago - GlobeNewsWire

Evaxion granted 180-day compliance extension by Nasdaq as it restores equity above minimum requirement

COPENHAGEN, Denmark, January 28, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has received notice...

6 months ago - GlobeNewsWire

Evaxion announces completion of ADS ratio change

COPENHAGEN, Denmark, January 14, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, to...

7 months ago - GlobeNewsWire

Evaxion announces extension to January 14, 2025, of plan to implement ADS ratio change

COPENHAGEN, Denmark, January 10, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced tha...

7 months ago - GlobeNewsWire

Evaxion announces plan to implement ADS ratio change

COPENHAGEN, Denmark, December 30, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced th...

7 months ago - GlobeNewsWire

Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1

COPENHAGEN, Denmark, November 12, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces new posi...

9 months ago - GlobeNewsWire

Evaxion announces business update and third quarter 2024 financial results

COPENHAGEN, Denmark, October 31, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business u...

9 months ago - GlobeNewsWire

Evaxion to announce business update and third quarter 2024 financial results on October 31

COPENHAGEN, Denmark, October 28, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a busi...

9 months ago - GlobeNewsWire